Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension, Pulmonary | 42 | 2024 | 1580 | 5.940 |
Why?
|
Aldosterone | 15 | 2023 | 869 | 3.180 |
Why?
|
Pulmonary Artery | 19 | 2024 | 1927 | 2.230 |
Why?
|
Glucosephosphate Dehydrogenase | 16 | 2020 | 208 | 1.920 |
Why?
|
Vascular Diseases | 10 | 2022 | 1160 | 1.630 |
Why?
|
Endothelium, Vascular | 22 | 2017 | 4433 | 1.470 |
Why?
|
Muscle, Smooth, Vascular | 15 | 2024 | 1492 | 1.440 |
Why?
|
Oxidative Stress | 20 | 2016 | 3113 | 1.170 |
Why?
|
Ventricular Dysfunction, Right | 9 | 2023 | 628 | 1.140 |
Why?
|
Angioplasty, Balloon, Coronary | 5 | 2022 | 1725 | 1.030 |
Why?
|
Sarcoplasmic Reticulum Calcium-Transporting ATPases | 6 | 2021 | 128 | 1.000 |
Why?
|
Ventricular Function, Right | 7 | 2023 | 617 | 0.970 |
Why?
|
Pulmonary Circulation | 5 | 2022 | 737 | 0.970 |
Why?
|
Hemodynamics | 13 | 2024 | 4160 | 0.970 |
Why?
|
Spironolactone | 8 | 2016 | 409 | 0.940 |
Why?
|
Nitric Oxide | 12 | 2012 | 2135 | 0.870 |
Why?
|
Neointima | 2 | 2014 | 133 | 0.870 |
Why?
|
Myocytes, Smooth Muscle | 8 | 2024 | 699 | 0.870 |
Why?
|
Hyperaldosteronism | 4 | 2023 | 247 | 0.810 |
Why?
|
Cardiovascular Diseases | 13 | 2024 | 15498 | 0.790 |
Why?
|
Core Binding Factor Alpha 1 Subunit | 2 | 2012 | 158 | 0.770 |
Why?
|
Vasoconstriction | 3 | 2022 | 592 | 0.740 |
Why?
|
Glutathione Peroxidase | 8 | 2011 | 258 | 0.730 |
Why?
|
Blood Vessels | 4 | 2016 | 1113 | 0.720 |
Why?
|
Remote Sensing Technology | 1 | 2021 | 92 | 0.710 |
Why?
|
Coronary Angiography | 9 | 2024 | 4470 | 0.700 |
Why?
|
Bone Morphogenetic Protein 2 | 2 | 2012 | 343 | 0.700 |
Why?
|
Receptors, Mineralocorticoid | 4 | 2016 | 163 | 0.700 |
Why?
|
Coronary Vessels | 8 | 2024 | 3095 | 0.690 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2021 | 241 | 0.680 |
Why?
|
Radiation Protection | 1 | 2023 | 424 | 0.680 |
Why?
|
Heart Failure | 11 | 2024 | 11669 | 0.680 |
Why?
|
Reactive Oxygen Species | 17 | 2015 | 2137 | 0.660 |
Why?
|
Antioxidants | 11 | 2016 | 1668 | 0.650 |
Why?
|
Calcinosis | 5 | 2020 | 1469 | 0.630 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 5 | 2021 | 322 | 0.630 |
Why?
|
Coronary Artery Disease | 10 | 2024 | 6403 | 0.630 |
Why?
|
Hypertension | 9 | 2024 | 8529 | 0.620 |
Why?
|
Plague | 1 | 2018 | 19 | 0.600 |
Why?
|
Oxidants | 4 | 2013 | 169 | 0.590 |
Why?
|
Endothelial Cells | 9 | 2018 | 3548 | 0.590 |
Why?
|
Glucosephosphate Dehydrogenase Deficiency | 8 | 2012 | 94 | 0.570 |
Why?
|
Models, Cardiovascular | 3 | 2024 | 981 | 0.540 |
Why?
|
MicroRNAs | 3 | 2020 | 3805 | 0.540 |
Why?
|
Health Status Indicators | 1 | 2021 | 969 | 0.530 |
Why?
|
Lung | 8 | 2024 | 9998 | 0.520 |
Why?
|
Humans | 134 | 2024 | 760617 | 0.510 |
Why?
|
Autonomic Pathways | 1 | 2015 | 31 | 0.510 |
Why?
|
Antigens, CD34 | 2 | 2018 | 658 | 0.500 |
Why?
|
Lung Diseases | 4 | 2024 | 1909 | 0.500 |
Why?
|
Sex Characteristics | 2 | 2021 | 2637 | 0.490 |
Why?
|
Oxidoreductases | 2 | 2009 | 412 | 0.490 |
Why?
|
Endomyocardial Fibrosis | 1 | 2014 | 41 | 0.480 |
Why?
|
Nitric Oxide Synthase Type III | 4 | 2012 | 705 | 0.480 |
Why?
|
Pulmonary Fibrosis | 2 | 2019 | 505 | 0.470 |
Why?
|
Denervation | 1 | 2015 | 265 | 0.470 |
Why?
|
Vascular Resistance | 4 | 2020 | 930 | 0.470 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 681 | 0.470 |
Why?
|
Lipocalins | 1 | 2015 | 161 | 0.460 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 250 | 0.450 |
Why?
|
Pulmonary Wedge Pressure | 5 | 2024 | 273 | 0.450 |
Why?
|
Ventricular Remodeling | 5 | 2016 | 1265 | 0.450 |
Why?
|
Monocrotaline | 1 | 2013 | 26 | 0.450 |
Why?
|
Pulmonary Veins | 2 | 2021 | 716 | 0.440 |
Why?
|
Phenylpropionates | 1 | 2013 | 35 | 0.430 |
Why?
|
Stem Cells | 4 | 2018 | 3516 | 0.430 |
Why?
|
Diphosphates | 1 | 2013 | 84 | 0.430 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2006 | 577 | 0.420 |
Why?
|
Cardiovascular System | 1 | 2020 | 834 | 0.420 |
Why?
|
Fractional Flow Reserve, Myocardial | 3 | 2024 | 324 | 0.420 |
Why?
|
Connective Tissue Diseases | 1 | 2015 | 285 | 0.410 |
Why?
|
Aorta | 6 | 2020 | 2041 | 0.410 |
Why?
|
Receptor, Endothelin B | 1 | 2012 | 46 | 0.410 |
Why?
|
Obesity, Abdominal | 1 | 2015 | 373 | 0.390 |
Why?
|
Cardiac Output, Low | 1 | 2012 | 191 | 0.390 |
Why?
|
Coronary Aneurysm | 1 | 2014 | 232 | 0.390 |
Why?
|
Heart Ventricles | 6 | 2023 | 3796 | 0.380 |
Why?
|
Vasodilation | 5 | 2016 | 962 | 0.380 |
Why?
|
Pyridazines | 1 | 2013 | 201 | 0.380 |
Why?
|
Metabolomics | 1 | 2021 | 1656 | 0.380 |
Why?
|
Neurotransmitter Agents | 1 | 2015 | 665 | 0.370 |
Why?
|
Progeria | 1 | 2013 | 188 | 0.370 |
Why?
|
Systems Biology | 2 | 2018 | 481 | 0.370 |
Why?
|
Oncogene Proteins | 1 | 2015 | 718 | 0.370 |
Why?
|
Research Report | 3 | 2021 | 367 | 0.370 |
Why?
|
11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2010 | 29 | 0.370 |
Why?
|
Signal Transduction | 11 | 2024 | 23416 | 0.350 |
Why?
|
Biological Evolution | 1 | 2016 | 1070 | 0.350 |
Why?
|
Delayed Diagnosis | 1 | 2014 | 463 | 0.350 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 833 | 0.350 |
Why?
|
Up-Regulation | 4 | 2020 | 4117 | 0.350 |
Why?
|
Diuretics | 1 | 2013 | 611 | 0.340 |
Why?
|
Cells, Cultured | 18 | 2020 | 18937 | 0.340 |
Why?
|
Oxidation-Reduction | 11 | 2013 | 2231 | 0.340 |
Why?
|
Acute Coronary Syndrome | 2 | 2014 | 2190 | 0.340 |
Why?
|
Health Behavior | 1 | 2021 | 2643 | 0.340 |
Why?
|
Nanoparticles | 1 | 2021 | 1957 | 0.340 |
Why?
|
Calcium | 2 | 2022 | 5717 | 0.330 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 536 | 0.330 |
Why?
|
Vasodilator Agents | 4 | 2020 | 973 | 0.330 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2010 | 175 | 0.330 |
Why?
|
Computational Biology | 3 | 2021 | 3509 | 0.330 |
Why?
|
Microcirculation | 1 | 2014 | 1272 | 0.330 |
Why?
|
Animals | 57 | 2024 | 168201 | 0.330 |
Why?
|
Free Radicals | 1 | 2009 | 238 | 0.330 |
Why?
|
Phosphoproteins | 2 | 2018 | 2446 | 0.330 |
Why?
|
Coronary Stenosis | 3 | 2024 | 794 | 0.320 |
Why?
|
Serpins | 1 | 2010 | 247 | 0.320 |
Why?
|
Health Status | 2 | 2021 | 4075 | 0.320 |
Why?
|
Thrombosis | 6 | 2020 | 2943 | 0.320 |
Why?
|
Peripheral Arterial Disease | 1 | 2020 | 1271 | 0.320 |
Why?
|
Receptors, Glucocorticoid | 1 | 2010 | 305 | 0.310 |
Why?
|
Xanthine Oxidase | 2 | 2006 | 69 | 0.310 |
Why?
|
Computer Simulation | 3 | 2021 | 6233 | 0.300 |
Why?
|
Phenotype | 9 | 2023 | 16571 | 0.300 |
Why?
|
Coronary Circulation | 1 | 2014 | 1569 | 0.300 |
Why?
|
Guanylate Cyclase | 1 | 2009 | 205 | 0.300 |
Why?
|
Gene Expression Regulation | 5 | 2020 | 11874 | 0.300 |
Why?
|
Antihypertensive Agents | 2 | 2018 | 2016 | 0.300 |
Why?
|
Disulfides | 2 | 2009 | 464 | 0.290 |
Why?
|
Cell Hypoxia | 2 | 2015 | 656 | 0.290 |
Why?
|
Catheter Ablation | 2 | 2022 | 2634 | 0.290 |
Why?
|
Neovascularization, Physiologic | 4 | 2018 | 1349 | 0.290 |
Why?
|
Proteomics | 1 | 2021 | 3836 | 0.280 |
Why?
|
Osteoblasts | 1 | 2012 | 1141 | 0.280 |
Why?
|
Sleep | 2 | 2023 | 4758 | 0.270 |
Why?
|
NADP | 4 | 2009 | 227 | 0.270 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2008 | 445 | 0.270 |
Why?
|
Coronary Disease | 4 | 2021 | 5912 | 0.270 |
Why?
|
DNA Damage | 1 | 2016 | 2446 | 0.260 |
Why?
|
Rats | 15 | 2024 | 23717 | 0.260 |
Why?
|
Atherosclerosis | 3 | 2014 | 3400 | 0.260 |
Why?
|
Endoplasmic Reticulum | 1 | 2011 | 1132 | 0.250 |
Why?
|
Proto-Oncogene Proteins | 3 | 2019 | 4512 | 0.250 |
Why?
|
Myocardial Infarction | 6 | 2014 | 11459 | 0.250 |
Why?
|
Embolization, Therapeutic | 1 | 2015 | 1418 | 0.250 |
Why?
|
Oxygenases | 1 | 2005 | 59 | 0.250 |
Why?
|
Cardiology | 1 | 2016 | 1656 | 0.240 |
Why?
|
Ventricular Dysfunction | 1 | 2006 | 144 | 0.240 |
Why?
|
Atrial Fibrillation | 3 | 2022 | 5031 | 0.240 |
Why?
|
Biomedical Research | 2 | 2021 | 3426 | 0.240 |
Why?
|
Cell Proliferation | 9 | 2020 | 10432 | 0.240 |
Why?
|
Coronary Thrombosis | 2 | 2005 | 440 | 0.240 |
Why?
|
Apoptosis | 7 | 2016 | 9476 | 0.240 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2014 | 1426 | 0.230 |
Why?
|
Platelet Activation | 3 | 2010 | 646 | 0.230 |
Why?
|
Gene Transfer Techniques | 4 | 2016 | 1202 | 0.230 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2006 | 2745 | 0.220 |
Why?
|
Nitro Compounds | 1 | 2003 | 74 | 0.220 |
Why?
|
Fibrinolytic Agents | 2 | 2008 | 2073 | 0.220 |
Why?
|
Tachyphylaxis | 1 | 2003 | 54 | 0.220 |
Why?
|
Complement Activation | 2 | 2020 | 445 | 0.220 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2019 | 2895 | 0.220 |
Why?
|
Male | 50 | 2024 | 360358 | 0.220 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2011 | 1169 | 0.220 |
Why?
|
Dexamethasone | 1 | 2010 | 1947 | 0.210 |
Why?
|
Exercise Tolerance | 4 | 2024 | 836 | 0.210 |
Why?
|
Fibrosis | 4 | 2020 | 2045 | 0.210 |
Why?
|
Pulmonary Embolism | 1 | 2016 | 2568 | 0.210 |
Why?
|
Cattle | 6 | 2012 | 3841 | 0.210 |
Why?
|
Early Diagnosis | 1 | 2008 | 1185 | 0.210 |
Why?
|
X-Rays | 1 | 2023 | 307 | 0.210 |
Why?
|
Rats, Sprague-Dawley | 7 | 2020 | 8166 | 0.210 |
Why?
|
Aortic Valve | 1 | 2012 | 1955 | 0.200 |
Why?
|
Tissue Plasminogen Activator | 1 | 2008 | 1163 | 0.200 |
Why?
|
Wound Healing | 1 | 2013 | 2802 | 0.200 |
Why?
|
Treatment Outcome | 12 | 2023 | 64568 | 0.200 |
Why?
|
Pterins | 1 | 2001 | 11 | 0.200 |
Why?
|
Cyclic AMP | 3 | 2020 | 1463 | 0.200 |
Why?
|
Obesity | 2 | 2014 | 12933 | 0.190 |
Why?
|
Hydrodynamics | 2 | 2021 | 168 | 0.190 |
Why?
|
Pulmonary Edema | 1 | 2024 | 407 | 0.190 |
Why?
|
Angina, Unstable | 2 | 2006 | 888 | 0.190 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2024 | 619 | 0.180 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 673 | 0.180 |
Why?
|
Education | 2 | 2021 | 534 | 0.180 |
Why?
|
Nitric Oxide Synthase | 5 | 2009 | 908 | 0.180 |
Why?
|
Ticlopidine | 1 | 2005 | 730 | 0.170 |
Why?
|
Lymphokines | 1 | 2003 | 925 | 0.170 |
Why?
|
Glutathione | 7 | 2016 | 582 | 0.170 |
Why?
|
Aortic Valve Stenosis | 1 | 2012 | 2003 | 0.170 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2006 | 829 | 0.170 |
Why?
|
Second Messenger Systems | 1 | 2020 | 202 | 0.170 |
Why?
|
Scleroderma, Systemic | 1 | 2023 | 344 | 0.170 |
Why?
|
Predictive Value of Tests | 4 | 2024 | 15251 | 0.160 |
Why?
|
Female | 40 | 2024 | 392148 | 0.160 |
Why?
|
Periodicity | 1 | 2000 | 347 | 0.160 |
Why?
|
Random Allocation | 2 | 2014 | 2392 | 0.160 |
Why?
|
Hydrogen Peroxide | 3 | 2009 | 730 | 0.160 |
Why?
|
Endothelium | 2 | 2020 | 764 | 0.160 |
Why?
|
Stroke Volume | 3 | 2024 | 5486 | 0.160 |
Why?
|
Autistic Disorder | 1 | 2008 | 1219 | 0.150 |
Why?
|
Collagen Type III | 1 | 2018 | 91 | 0.150 |
Why?
|
Disease Models, Animal | 12 | 2020 | 18221 | 0.150 |
Why?
|
Middle Aged | 26 | 2024 | 220584 | 0.150 |
Why?
|
Forecasting | 2 | 2018 | 2924 | 0.150 |
Why?
|
Superoxides | 5 | 2012 | 387 | 0.150 |
Why?
|
Ankle Brachial Index | 1 | 2018 | 163 | 0.150 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2013 | 1650 | 0.150 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 3705 | 0.150 |
Why?
|
Glucose | 3 | 2016 | 4345 | 0.150 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2017 | 46 | 0.140 |
Why?
|
Janus Kinase 2 | 1 | 2021 | 560 | 0.140 |
Why?
|
Hemorrhage | 2 | 2006 | 3418 | 0.140 |
Why?
|
Exercise Test | 4 | 2024 | 2127 | 0.140 |
Why?
|
Dependovirus | 2 | 2019 | 712 | 0.140 |
Why?
|
Organoselenium Compounds | 1 | 2016 | 21 | 0.140 |
Why?
|
Azoles | 1 | 2016 | 22 | 0.140 |
Why?
|
Down-Regulation | 3 | 2013 | 2915 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 2 | 2013 | 47 | 0.130 |
Why?
|
Folic Acid | 1 | 2003 | 1323 | 0.130 |
Why?
|
Dual-Specificity Phosphatases | 2 | 2013 | 71 | 0.130 |
Why?
|
Cyclic GMP | 5 | 2011 | 395 | 0.130 |
Why?
|
Antibodies, Monoclonal | 2 | 2013 | 9172 | 0.130 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15908 | 0.130 |
Why?
|
Nitrates | 1 | 1997 | 263 | 0.120 |
Why?
|
Diet | 1 | 2013 | 8048 | 0.120 |
Why?
|
Adenosine Monophosphate | 1 | 2016 | 231 | 0.120 |
Why?
|
Monitoring, Physiologic | 1 | 2023 | 1779 | 0.120 |
Why?
|
Brachial Artery | 1 | 2016 | 366 | 0.120 |
Why?
|
Coronary Vessel Anomalies | 1 | 2018 | 307 | 0.120 |
Why?
|
Renin-Angiotensin System | 2 | 2020 | 737 | 0.120 |
Why?
|
Caveolin 1 | 1 | 2016 | 255 | 0.120 |
Why?
|
Swine | 5 | 2017 | 5907 | 0.120 |
Why?
|
Heart Diseases | 1 | 2008 | 2778 | 0.120 |
Why?
|
Endothelin-1 | 2 | 2015 | 302 | 0.120 |
Why?
|
Thrombophilia | 2 | 2009 | 306 | 0.120 |
Why?
|
Coronary Restenosis | 1 | 2017 | 396 | 0.120 |
Why?
|
Angina Pectoris | 1 | 2018 | 959 | 0.110 |
Why?
|
Heart Failure, Systolic | 1 | 2015 | 135 | 0.110 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 1222 | 0.110 |
Why?
|
Pharmacogenetics | 1 | 2018 | 675 | 0.110 |
Why?
|
Lipid Peroxidation | 3 | 2012 | 271 | 0.110 |
Why?
|
Graft Occlusion, Vascular | 1 | 2017 | 537 | 0.110 |
Why?
|
Risk Factors | 12 | 2024 | 74115 | 0.110 |
Why?
|
Aged | 22 | 2024 | 169042 | 0.110 |
Why?
|
Myocardium | 3 | 2017 | 4724 | 0.110 |
Why?
|
Genetic Diseases, Inborn | 1 | 2018 | 604 | 0.110 |
Why?
|
Aspirin | 1 | 2005 | 3127 | 0.110 |
Why?
|
Demography | 1 | 2018 | 1643 | 0.110 |
Why?
|
Stents | 1 | 2005 | 3178 | 0.110 |
Why?
|
Peptides | 1 | 2005 | 4354 | 0.100 |
Why?
|
Ultrasonography | 2 | 2024 | 5964 | 0.100 |
Why?
|
United States | 11 | 2021 | 72272 | 0.100 |
Why?
|
Genetic Vectors | 2 | 2019 | 3392 | 0.100 |
Why?
|
Fibroblasts | 2 | 2020 | 4137 | 0.100 |
Why?
|
Sympathetic Nervous System | 1 | 2015 | 519 | 0.100 |
Why?
|
Postoperative Complications | 1 | 2014 | 15612 | 0.100 |
Why?
|
Pentosephosphates | 1 | 2011 | 6 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1086 | 0.100 |
Why?
|
Glucose-6-Phosphate | 1 | 2011 | 29 | 0.100 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2017 | 499 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10199 | 0.100 |
Why?
|
Cardiovascular Agents | 1 | 2018 | 839 | 0.100 |
Why?
|
Myocardial Contraction | 3 | 2014 | 1515 | 0.100 |
Why?
|
Pilot Projects | 3 | 2015 | 8618 | 0.100 |
Why?
|
Hyperhomocysteinemia | 2 | 2003 | 118 | 0.100 |
Why?
|
Myocytes, Cardiac | 2 | 2015 | 1667 | 0.090 |
Why?
|
Mice | 19 | 2020 | 81368 | 0.090 |
Why?
|
Catheterization | 1 | 2016 | 1428 | 0.090 |
Why?
|
Thrombolytic Therapy | 2 | 2001 | 2055 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7995 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4341 | 0.090 |
Why?
|
United States Department of Veterans Affairs | 1 | 2016 | 928 | 0.090 |
Why?
|
Sulfhydryl Compounds | 1 | 2012 | 301 | 0.090 |
Why?
|
S-Nitrosothiols | 1 | 2010 | 35 | 0.090 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 614 | 0.090 |
Why?
|
Models, Biological | 4 | 2020 | 9461 | 0.090 |
Why?
|
Cell Movement | 3 | 2020 | 5200 | 0.090 |
Why?
|
Constriction, Pathologic | 3 | 2020 | 1096 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 4570 | 0.090 |
Why?
|
Drug Discovery | 1 | 2018 | 1051 | 0.090 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2010 | 128 | 0.090 |
Why?
|
Dehydroepiandrosterone | 2 | 2001 | 258 | 0.090 |
Why?
|
Abnormalities, Multiple | 1 | 2017 | 1422 | 0.090 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 3204 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 20556 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1600 | 0.080 |
Why?
|
Oligonucleotides, Antisense | 2 | 2003 | 458 | 0.080 |
Why?
|
Life Style | 1 | 2021 | 3904 | 0.080 |
Why?
|
Angioplasty, Balloon | 1 | 2013 | 589 | 0.080 |
Why?
|
Multiprotein Complexes | 1 | 2016 | 1118 | 0.080 |
Why?
|
Drug Approval | 1 | 2016 | 812 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6305 | 0.080 |
Why?
|
Brachytherapy | 1 | 2017 | 1223 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2278 | 0.080 |
Why?
|
Blood Platelets | 2 | 2011 | 2478 | 0.080 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 2 | 2012 | 485 | 0.080 |
Why?
|
Adult | 11 | 2024 | 220969 | 0.080 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 318 | 0.080 |
Why?
|
Time Factors | 6 | 2021 | 39913 | 0.080 |
Why?
|
Catalase | 2 | 2009 | 218 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2871 | 0.080 |
Why?
|
Echocardiography | 3 | 2022 | 4987 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2734 | 0.080 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2009 | 94 | 0.080 |
Why?
|
Mitochondria, Liver | 1 | 2009 | 190 | 0.080 |
Why?
|
Genotype | 3 | 2020 | 12978 | 0.070 |
Why?
|
Lipid Metabolism | 1 | 2016 | 1896 | 0.070 |
Why?
|
Nitric Oxide Donors | 2 | 2009 | 126 | 0.070 |
Why?
|
alpha-Crystallin B Chain | 1 | 2007 | 24 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4533 | 0.070 |
Why?
|
Mice, Inbred C57BL | 4 | 2020 | 22115 | 0.070 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2011 | 485 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 1454 | 0.070 |
Why?
|
Cysteine | 1 | 2012 | 891 | 0.070 |
Why?
|
Selenoproteins | 1 | 2009 | 215 | 0.070 |
Why?
|
NF-kappa B | 2 | 2013 | 2481 | 0.070 |
Why?
|
Inflammation | 3 | 2021 | 10760 | 0.070 |
Why?
|
bcl-2-Associated X Protein | 2 | 2009 | 282 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2057 | 0.070 |
Why?
|
COS Cells | 1 | 2009 | 1130 | 0.070 |
Why?
|
Cell Adhesion | 1 | 2013 | 3088 | 0.070 |
Why?
|
Hemorrhagic Disorders | 1 | 2006 | 34 | 0.070 |
Why?
|
Cyclic AMP Response Element Modulator | 1 | 2007 | 88 | 0.070 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2007 | 292 | 0.070 |
Why?
|
Alzheimer Disease | 1 | 2008 | 8601 | 0.070 |
Why?
|
Blotting, Western | 2 | 2010 | 5034 | 0.070 |
Why?
|
Endocrine System Diseases | 1 | 2008 | 249 | 0.070 |
Why?
|
Genetic Variation | 2 | 2018 | 6561 | 0.070 |
Why?
|
DNA Methylation | 1 | 2020 | 4391 | 0.060 |
Why?
|
Albuminuria | 1 | 2009 | 655 | 0.060 |
Why?
|
Nitric Oxide Synthase Type II | 2 | 2006 | 517 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13347 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 10754 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 29600 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3533 | 0.060 |
Why?
|
Blotting, Northern | 1 | 2007 | 1545 | 0.060 |
Why?
|
Tomography, Optical Coherence | 2 | 2017 | 2916 | 0.060 |
Why?
|
Purinergic P2 Receptor Antagonists | 1 | 2005 | 67 | 0.060 |
Why?
|
Stress, Mechanical | 2 | 2019 | 1674 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 1723 | 0.060 |
Why?
|
Receptors, Purinergic P2Y12 | 1 | 2005 | 115 | 0.060 |
Why?
|
Allopurinol | 1 | 2006 | 198 | 0.060 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 1483 | 0.060 |
Why?
|
History, 21st Century | 1 | 2010 | 1565 | 0.060 |
Why?
|
Premedication | 1 | 2005 | 245 | 0.060 |
Why?
|
Triazenes | 1 | 2003 | 8 | 0.060 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2007 | 852 | 0.060 |
Why?
|
Blood Pressure | 2 | 2017 | 8472 | 0.060 |
Why?
|
Mice, Knockout | 7 | 2020 | 14389 | 0.060 |
Why?
|
Peroxynitrous Acid | 1 | 2003 | 40 | 0.060 |
Why?
|
Young Adult | 4 | 2021 | 59179 | 0.060 |
Why?
|
HEK293 Cells | 1 | 2013 | 4269 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2010 | 1755 | 0.060 |
Why?
|
Cell Adhesion Molecules | 1 | 2010 | 1602 | 0.060 |
Why?
|
Immunoblotting | 1 | 2007 | 1646 | 0.050 |
Why?
|
Complement C3 | 2 | 2020 | 434 | 0.050 |
Why?
|
Xanthine | 1 | 2003 | 11 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2018 | 58894 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2016 | 12334 | 0.050 |
Why?
|
Kynurenine | 1 | 2023 | 141 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2008 | 8516 | 0.050 |
Why?
|
Arteriosclerosis | 3 | 2002 | 1056 | 0.050 |
Why?
|
Aging | 2 | 2020 | 8699 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2020 | 22148 | 0.050 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 3 | 2011 | 691 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2016 | 3954 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3680 | 0.050 |
Why?
|
DNA Primers | 1 | 2007 | 2817 | 0.050 |
Why?
|
Retrospective Studies | 9 | 2024 | 80566 | 0.050 |
Why?
|
History, 20th Century | 1 | 2010 | 2764 | 0.050 |
Why?
|
Insulin-Secreting Cells | 1 | 2009 | 898 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4803 | 0.050 |
Why?
|
Superoxide Dismutase | 1 | 2005 | 593 | 0.050 |
Why?
|
Angiotensin II | 1 | 2005 | 849 | 0.050 |
Why?
|
Nitroglycerin | 1 | 2003 | 329 | 0.050 |
Why?
|
Lipopolysaccharides | 1 | 2010 | 2202 | 0.050 |
Why?
|
Biological Availability | 1 | 2003 | 389 | 0.050 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2024 | 269 | 0.050 |
Why?
|
Mutation | 4 | 2018 | 30016 | 0.050 |
Why?
|
Veterans | 1 | 2016 | 2649 | 0.050 |
Why?
|
Mice, Mutant Strains | 4 | 2009 | 1748 | 0.050 |
Why?
|
Electrocardiography | 2 | 2008 | 6346 | 0.050 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2003 | 748 | 0.050 |
Why?
|
Chronic Disease | 1 | 2016 | 9311 | 0.050 |
Why?
|
Pteridines | 1 | 2001 | 47 | 0.050 |
Why?
|
Tryptophan | 1 | 2023 | 482 | 0.050 |
Why?
|
Glutathione Reductase | 1 | 2000 | 25 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2009 | 1375 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7389 | 0.050 |
Why?
|
Creatinine | 1 | 2006 | 1896 | 0.050 |
Why?
|
Tyrosine | 3 | 2016 | 1440 | 0.040 |
Why?
|
Shear Strength | 1 | 2021 | 160 | 0.040 |
Why?
|
NADH, NADPH Oxidoreductases | 1 | 2000 | 94 | 0.040 |
Why?
|
Intracellular Fluid | 1 | 2000 | 201 | 0.040 |
Why?
|
Dinoprost | 2 | 2016 | 138 | 0.040 |
Why?
|
Glycolysis | 1 | 2024 | 835 | 0.040 |
Why?
|
Secretory Pathway | 1 | 2020 | 53 | 0.040 |
Why?
|
Myocardial Reperfusion Injury | 1 | 2004 | 481 | 0.040 |
Why?
|
Membrane Potentials | 1 | 2003 | 1089 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12661 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2013 | 15828 | 0.040 |
Why?
|
Cell Line | 4 | 2010 | 15576 | 0.040 |
Why?
|
Complement Factor B | 1 | 2020 | 57 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2006 | 1443 | 0.040 |
Why?
|
Cytosol | 1 | 2003 | 886 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2011 | 5780 | 0.040 |
Why?
|
Liver | 2 | 2016 | 7512 | 0.040 |
Why?
|
Blood Glucose | 2 | 2016 | 6390 | 0.040 |
Why?
|
Complement C5 | 1 | 2020 | 103 | 0.040 |
Why?
|
Pyrophosphatases | 1 | 2020 | 142 | 0.040 |
Why?
|
Blood Transfusion | 1 | 2006 | 1299 | 0.040 |
Why?
|
Complement Pathway, Alternative | 1 | 2020 | 113 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2006 | 1788 | 0.040 |
Why?
|
Hospitalization | 2 | 2018 | 10704 | 0.040 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2020 | 201 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2019 | 9586 | 0.040 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 161 | 0.040 |
Why?
|
Diabetes Mellitus | 2 | 2016 | 5835 | 0.040 |
Why?
|
Cell Survival | 3 | 2016 | 5780 | 0.040 |
Why?
|
Carbon Monoxide | 1 | 2022 | 547 | 0.040 |
Why?
|
Review Literature as Topic | 1 | 2021 | 347 | 0.040 |
Why?
|
Cohort Studies | 3 | 2024 | 41457 | 0.040 |
Why?
|
Exercise | 1 | 2015 | 5886 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2008 | 6520 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2007 | 6224 | 0.040 |
Why?
|
Women's Health | 1 | 2008 | 2065 | 0.040 |
Why?
|
Pulmonary Gas Exchange | 1 | 2020 | 379 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2007 | 2570 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6483 | 0.040 |
Why?
|
Smad3 Protein | 1 | 2018 | 166 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2006 | 2178 | 0.040 |
Why?
|
Survival Analysis | 2 | 2020 | 10073 | 0.040 |
Why?
|
Hemostasis | 2 | 2002 | 469 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15689 | 0.040 |
Why?
|
Shock, Cardiogenic | 1 | 2003 | 709 | 0.040 |
Why?
|
Patient Positioning | 1 | 2020 | 326 | 0.040 |
Why?
|
Injections, Intra-Arterial | 1 | 2017 | 181 | 0.040 |
Why?
|
Parasympathomimetics | 1 | 2016 | 27 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2017 | 39063 | 0.030 |
Why?
|
Gene Expression | 2 | 2020 | 7568 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2011 | 476 | 0.030 |
Why?
|
Rabbits | 1 | 2003 | 4770 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2012 | 11514 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1404 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2001 | 790 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2011 | 1128 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 4845 | 0.030 |
Why?
|
Isoindoles | 1 | 2016 | 35 | 0.030 |
Why?
|
Aldehyde Reductase | 1 | 2016 | 70 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2020 | 850 | 0.030 |
Why?
|
Methacholine Chloride | 1 | 2016 | 220 | 0.030 |
Why?
|
Respiratory Function Tests | 1 | 2021 | 1683 | 0.030 |
Why?
|
Plethysmography | 1 | 2016 | 175 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 888 | 0.030 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2016 | 94 | 0.030 |
Why?
|
Primary Prevention | 1 | 2024 | 1185 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 103 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2005 | 3492 | 0.030 |
Why?
|
Resistin | 1 | 2016 | 172 | 0.030 |
Why?
|
Lung Diseases, Interstitial | 1 | 2024 | 918 | 0.030 |
Why?
|
Streptokinase | 1 | 1995 | 186 | 0.030 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2010 | 2249 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2016 | 510 | 0.030 |
Why?
|
Cell Division | 1 | 2003 | 4457 | 0.030 |
Why?
|
Gene Knockdown Techniques | 2 | 2011 | 1608 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2006 | 2090 | 0.030 |
Why?
|
Cardiomyopathies | 1 | 2007 | 1948 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2019 | 871 | 0.030 |
Why?
|
Heart | 2 | 2022 | 4403 | 0.030 |
Why?
|
Cerebral Hemorrhage | 1 | 2006 | 2641 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20074 | 0.030 |
Why?
|
beta-Galactosidase | 1 | 2016 | 574 | 0.030 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 1995 | 325 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2018 | 794 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1376 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17878 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2011 | 3591 | 0.030 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2016 | 284 | 0.030 |
Why?
|
Forearm | 1 | 2016 | 427 | 0.030 |
Why?
|
Arteries | 1 | 2018 | 1122 | 0.030 |
Why?
|
Aerosols | 1 | 2016 | 635 | 0.030 |
Why?
|
Hypertriglyceridemia | 1 | 2016 | 293 | 0.030 |
Why?
|
Transfection | 1 | 2001 | 5766 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 802 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2004 | 2110 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2112 | 0.030 |
Why?
|
Registries | 2 | 2006 | 8207 | 0.030 |
Why?
|
Protein Transport | 2 | 2012 | 1966 | 0.030 |
Why?
|
RNA, Small Interfering | 2 | 2012 | 3419 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 3800 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2017 | 1835 | 0.030 |
Why?
|
Kinetics | 1 | 2020 | 6370 | 0.030 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2003 | 2118 | 0.020 |
Why?
|
Oxygen | 1 | 2023 | 4226 | 0.020 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 675 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26049 | 0.020 |
Why?
|
Angiography | 1 | 2017 | 1596 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12116 | 0.020 |
Why?
|
Adolescent | 3 | 2016 | 88234 | 0.020 |
Why?
|
Cardiomegaly | 1 | 2014 | 590 | 0.020 |
Why?
|
Thiamine | 1 | 2012 | 160 | 0.020 |
Why?
|
Bleeding Time | 1 | 2011 | 83 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 2012 | 913 | 0.020 |
Why?
|
Length of Stay | 1 | 2005 | 6418 | 0.020 |
Why?
|
Pentose Phosphate Pathway | 1 | 2011 | 126 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2017 | 2509 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 23972 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2005 | 7847 | 0.020 |
Why?
|
Hep G2 Cells | 1 | 2011 | 378 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2079 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 4947 | 0.020 |
Why?
|
Mitochondria | 1 | 2003 | 3619 | 0.020 |
Why?
|
I-kappa B Kinase | 1 | 2011 | 249 | 0.020 |
Why?
|
Adenosine Diphosphate | 1 | 2011 | 422 | 0.020 |
Why?
|
Prosthesis Design | 1 | 2017 | 2114 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 472 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2011 | 433 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6474 | 0.020 |
Why?
|
Lipogenesis | 1 | 2011 | 214 | 0.020 |
Why?
|
Kidney Cortex | 1 | 2009 | 169 | 0.020 |
Why?
|
Oligonucleotides | 1 | 2012 | 566 | 0.020 |
Why?
|
S-Nitroso-N-Acetylpenicillamine | 1 | 2009 | 23 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2019 | 2872 | 0.020 |
Why?
|
Protein Phosphatase 2 | 1 | 2011 | 231 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3601 | 0.020 |
Why?
|
Uncoupling Agents | 1 | 2009 | 46 | 0.020 |
Why?
|
Nitroso Compounds | 1 | 2009 | 71 | 0.020 |
Why?
|
Complement Membrane Attack Complex | 1 | 2009 | 105 | 0.020 |
Why?
|
Dyslipidemias | 1 | 2016 | 868 | 0.020 |
Why?
|
Microvessels | 1 | 2013 | 577 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2009 | 211 | 0.020 |
Why?
|
Insulin | 2 | 2016 | 6593 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2017 | 1496 | 0.020 |
Why?
|
Heterozygote | 2 | 2009 | 2780 | 0.020 |
Why?
|
NG-Nitroarginine Methyl Ester | 1 | 2009 | 260 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12447 | 0.020 |
Why?
|
Triglycerides | 1 | 2016 | 2459 | 0.020 |
Why?
|
P-Selectin | 1 | 2011 | 599 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2016 | 12758 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2009 | 2456 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2016 | 1661 | 0.020 |
Why?
|
Selenocysteine | 1 | 2009 | 127 | 0.020 |
Why?
|
Platelet Aggregation | 1 | 2011 | 771 | 0.020 |
Why?
|
Placenta | 1 | 2017 | 1709 | 0.020 |
Why?
|
Recovery of Function | 1 | 2018 | 2978 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2010 | 876 | 0.020 |
Why?
|
Phosphorylation | 2 | 2011 | 8311 | 0.020 |
Why?
|
Cholesterol | 1 | 2016 | 2903 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1677 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4785 | 0.020 |
Why?
|
Sex Factors | 1 | 2001 | 10548 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2017 | 1642 | 0.020 |
Why?
|
Diet, Atherogenic | 1 | 2006 | 92 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2009 | 699 | 0.020 |
Why?
|
Calcification, Physiologic | 1 | 2006 | 170 | 0.020 |
Why?
|
Reperfusion Injury | 1 | 2012 | 1023 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2009 | 901 | 0.020 |
Why?
|
Protein Binding | 1 | 2018 | 9345 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12966 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1986 | 179 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2009 | 12142 | 0.020 |
Why?
|
Homeostasis | 1 | 2016 | 3321 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2016 | 5239 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2009 | 1202 | 0.020 |
Why?
|
Nitroprusside | 2 | 2000 | 272 | 0.010 |
Why?
|
Adenoviridae | 1 | 2009 | 1084 | 0.010 |
Why?
|
Homozygote | 1 | 2009 | 1776 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2016 | 3309 | 0.010 |
Why?
|
Mortality | 1 | 2016 | 2899 | 0.010 |
Why?
|
Hepatocytes | 1 | 2011 | 1231 | 0.010 |
Why?
|
Metalloporphyrins | 1 | 2004 | 41 | 0.010 |
Why?
|
Ribose | 1 | 2004 | 63 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8833 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1970 | 0.010 |
Why?
|
Glycine | 1 | 2007 | 661 | 0.010 |
Why?
|
Arginine | 1 | 2007 | 933 | 0.010 |
Why?
|
Hindlimb | 1 | 2005 | 513 | 0.010 |
Why?
|
Hypertrophy | 1 | 2005 | 560 | 0.010 |
Why?
|
Recurrence | 1 | 1995 | 8426 | 0.010 |
Why?
|
Survival Rate | 1 | 2017 | 12719 | 0.010 |
Why?
|
Adenosine Triphosphate | 1 | 2009 | 1988 | 0.010 |
Why?
|
Subcellular Fractions | 1 | 2003 | 531 | 0.010 |
Why?
|
Rupture, Spontaneous | 1 | 2002 | 362 | 0.010 |
Why?
|
Cystathionine beta-Synthase | 1 | 2000 | 27 | 0.010 |
Why?
|
F2-Isoprostanes | 1 | 2000 | 35 | 0.010 |
Why?
|
Lipid Peroxides | 1 | 2000 | 74 | 0.010 |
Why?
|
Stroke | 1 | 2022 | 9712 | 0.010 |
Why?
|
Osteogenesis | 1 | 2006 | 1270 | 0.010 |
Why?
|
Prospective Studies | 1 | 2024 | 54360 | 0.010 |
Why?
|
Acetylcholine | 1 | 2000 | 629 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2011 | 7583 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 26180 | 0.010 |
Why?
|
Ischemia | 1 | 2005 | 1884 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36402 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13495 | 0.010 |
Why?
|
Infant | 1 | 2017 | 36152 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29868 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9529 | 0.010 |
Why?
|
Child, Preschool | 1 | 2017 | 42188 | 0.010 |
Why?
|
Estrogen Replacement Therapy | 1 | 2000 | 1208 | 0.010 |
Why?
|
Cell Membrane | 1 | 2003 | 3680 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 1999 | 1141 | 0.010 |
Why?
|
Proteins | 1 | 2007 | 6030 | 0.010 |
Why?
|
Odds Ratio | 1 | 2003 | 9643 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2003 | 5293 | 0.010 |
Why?
|
Immunochemistry | 1 | 1986 | 116 | 0.000 |
Why?
|
Mesenteric Arteries | 1 | 1986 | 178 | 0.000 |
Why?
|
Histocytochemistry | 1 | 1986 | 696 | 0.000 |
Why?
|
Microspheres | 1 | 1986 | 782 | 0.000 |
Why?
|
Perfusion | 1 | 1986 | 1373 | 0.000 |
Why?
|
Cell Communication | 1 | 1986 | 1654 | 0.000 |
Why?
|